ITC’s final determination to terminate complaints by TPL followed December 2013 decision to reject patent claims by InterDigital

ME Newswire / Business Wire

SHENZHEN, China - Monday, March 3rd 2014

ZTE Corporation ("ZTE”) (H share stock code: 0763.HK / A share stock code: 000063.SZ), a publicly-listed global provider of telecommunications equipment, network solutions and mobile devices, welcomes the final determination of the United States International Trade Commission rejecting the claims of Technology Properties Limited LLC ("TPL”), which strengthened ZTE’s defenses against other intellectual property-related complaints.

The ITC terminated an investigation into TPL’s complaints alleging violations of Section 337 of the Tariff Act of 1930, after rejecting TPL’s claims of patent infringement. TPL initially filed the complaints in July 2012 against more than 10 respondents including ZTE, Samsung, HTC, LG and Huawei. The decision in the TPL case followed the ... Read more »

TOKYO - Saturday, March 1st 2014 [ME NewsWire]

(BUSINESS WIRE) Toshiba Corporation (TOKYO:6502) today announced that it has published the English-language edition of Toshiba Semiconductor & Storage Products Company Environmental Report 2013.

The Environmental Report covers environmental activities in fiscal 2012, including cases where our efforts to reduce environmental impact and greenhouse gas emission in the certain production processes of the semiconductor and storage products, as aspects of environmental management towards establishing a sustainable society. The report also includes community-based activities such as conservation of biodiversity and environmental communication.

The report’s "Introduction” provides a simple explanation of the company’s products, introduces semiconductor and storage products that contribute to the realization of smart communities, automotive products that are accelerating the computerization of automobiles, and enterprise SS ... Read more »

SAN DIEGO - Sunday, March 2nd 2014 [ME NewsWire]

    Significant unmet medical need in patients with asthma who continue to experience symptoms despite current standard treatments
    Improved understanding of tiotropium Respimat® as add-on treatment for patients with different severities of asthma
    Results add to existing evidence of efficacy and safety of tiotropium Respimat® in patients who remained symptomatic despite treatment with at least ICS†/LABA‡

2014 AAAAI Annual Meeting

(BUSINESS WIRE)-- For Media outside the U.S., Canada and UK

Boehringer Ingelheim today announced new data from large scale, Phase III studies showing that once-daily tiotropium delivered via the Respimat® inhaler was effective and well tolerated in patients across asthma severities. These data were presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2014 annual meeting in San Diego.

... Read more »

ME NewsWire/ Business Wire

RESEARCH TRIANGLE PARK, N.C. - Saturday, March 1st 2014

Marking today’s commemoration of ‘World Rare Disease Day’, Quintiles points to the 350 million people around the globe suffering from rare diseases – gathered together they would be the world’s third most populous nation – by highlighting its own contribution to tackling this challenge with a new collection of papers, podcasts and videos covering the latest developments and insights.

A rare disease is one that affects fewer than 200,000 Americans at any given time, according to the U.S. Food and Drug Administration.1 In Europe, a disease or disorder is defined as rare when it affects less than 1 in 2000.2 Milena Kanova, M.D., senior director, project management at Quintiles, explains. "Because rare diseases occur in relatively small numbers of people, patient recruitment can pose one of the greatest challenges in these type of clinical trials.”

Quintiles has been involved in ... Read more »